MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn
-
Upload
nadine-pena -
Category
Documents
-
view
23 -
download
0
description
Transcript of MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn
![Page 1: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/1.jpg)
MDUFMA Reauthorization:
Key Issues For Venture Capital
Jack LasersohnNVCA, Medical Industry Group
Vertical Group
![Page 2: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/2.jpg)
Venture Capital Improves the Lives of Millions
OVER 100 MILLION AMERICANShave been positively affected by venture-backed medical
innovations developed during the past 20 years
OVER 25 MILLION AMERICANShave their life extended or quality of life improved
every year, through the use of venture-backed diagnostic and therapeutic products
![Page 3: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/3.jpg)
Venture Capital Combats America’s Leading Causes of Death
Cause ofDeath
Deaths(2001)
Venture CapitalSupport
(20 years)
Venture BackedInnovative Treatments
HeartDisease
700,142 $22 billion angioplasty, minimally invasive
coronary bypass, electroablation,
implantable cardioverter-defibrillators (ICD’s),
automated external defibrillators (AED’s)
Integrilin, ReoPro
Cancer 553,768 $9 billion doppler ultrasound, minimally
invasive biopsy, PSA, MRI,
Avastin, Erbitux, Velcade,
Gliadel, Herceptin, RituxanStroke 163,538 $1.3 billion MRI, TPA
RespiratoryDisease
123,013 $19.5 billion FluMist, mechanical ventilators, pulse oximetry
![Page 4: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/4.jpg)
Biotechnology18%
Medical Devices and Equipment
9%
Healthcare Services
2%
Non-LS or HC71%
Life Sciences and Healthcare Services YTD Make Up Almost 1/3 of
Total Venture Investment
Source: PricewaterhouseCoopers/Venture Economics/National Venture Capital Association MoneyTree™ - 9m2004
![Page 5: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/5.jpg)
0
50
100
150
200# 1
st F
un
din
gs
in L
S
Co
s
19
83
19
84
19
85
19
86
19
87
19
88
19
89
19
90
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
9m
05
Number of First Financings forLS Companies Remains Strong
Source: PricewaterhouseCoopers/Venture Economics/National Venture Capital Association MoneyTree™
![Page 6: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/6.jpg)
Medical Device Startups
050
100150200250300350400450500
01-2Q
01-3Q
01-4Q
02-1Q
02-2Q
02-3Q
02-4Q
03-1Q
03-2Q
03-3Q
03-4Q
04-1Q
04-2Q
04-3Q
04-4Q
05-1Q
05-2Q
05-3Q
Source: PricewaterhouseCoopers/Venture Economics/National Venture Capital Association MoneyTree™
First Financings for Medical Device Companies
Millions
![Page 7: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/7.jpg)
Total Life Science Investment Is Much Greater than Pre-2000 Levels
$0
$2,000
$4,000
$6,000
$8,000
$10,000
$Million 2,57 3,31 3,71 5,17 8,52 6,01 5,17
1996 1997 1998 1999 2000 2001 2002 2003 20049m2005
Source: PricewaterhouseCoopers/Venture Economics/National Venture Capital Association MoneyTree™
![Page 8: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/8.jpg)
Number of LS CompaniesReceiving Funding Is Steady
0
100
200
300
400
500
600
700
# Companies 457 512 613 595 676 565 491
1996 1997 1998 1999 2000 2001 2002 2003 20049m2005
Source: PricewaterhouseCoopers/Venture Economics/National Venture Capital Association MoneyTree™
![Page 9: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/9.jpg)
Medical Device Industry Remains Strong
0
100
200
300
400
500
600
700
02-2Q
02-3Q
02-4Q
03-1Q
03-2Q
03-3Q
03-4Q
04-1Q
04-2Q
04-3Q
04-4Q
05-1Q
05-2Q
05-3Q
Source: PricewaterhouseCoopers/Venture Economics/National Venture Capital Association MoneyTree™
VC Funding for Medical Device CompaniesMillions
![Page 10: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/10.jpg)
0
25
50
75
100
1980 2000
Funding Requirements for Medical Devices
1980
$3 million
Balloon Angioplasty
2000
$75 million
Balloon Kyphoplasty
Start up to Profitability
![Page 11: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/11.jpg)
VC Funded Medical Devices
AngioplastyMRIPulse oximetryCardiac ablationICDs
AAA Stent GraftsBeating Heart SurgeryDisc ArthroplastyKyphoplastyNeurostimulation
Revolutionary, Not Evolutionary
![Page 12: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/12.jpg)
Novelty CreatesUnique Regulatory Challenges
• Education of CDRH Staff• Lack of Precedents and Pathways• Clinical Trial Design and Interpretation
![Page 13: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/13.jpg)
What VCs Are Doing in 2005
ProjectSpinal Nucleus replacementsDynamic spine stabilizationIntervention Treatment of Peripheral
AtherosclerosisBiodegradeable or Novel StentsNeurostimulation (Pain, Epilepsy, Depression)PFO ClosureVulnerable Plaque
Companies>15>15>15
>15>10
>10>10
![Page 14: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/14.jpg)
What VCs Are Doing in 2005
ProjectCartilage RepairStabilization of Heart FailureInterventions for AMIInterventions for Acute Stroke3rd Generation AAA GaffsArtificial Retinas3rd Generation LVADsAcute Interventions for DVTs
Companies>10
>10
>10
>5
>5
>5
>5
>5
![Page 15: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/15.jpg)
Performance Goals and Funding
• Substantial additional improvements possible in the timeliness, transparency and consistency of product reviews without a substantial increase in fees
• Assuring greater consistency, predictability and quality in the review of expedited PMAs and modular PMAs to be of the greatest importance
![Page 16: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/16.jpg)
Performance Goals and Funding
• FDA and sponsors should consider the potential for modest, non-application fees reflecting appropriate small business exemptions to increase the stability of MDUFMA funding and decrease existing application fees, as well as to better assure greater consistency, predictability and quality of premarket reviews
![Page 17: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/17.jpg)
Achieving First Cycle Approvals and Clearances
• FDA must recommit to consistency and clarity in its application of “least burdensome” principles to reduce unnecessary regulatory burden
• Congress should consider the necessity of additional statutory guidance to advance timely patient access to innovative treatments while ensuring CDRH seeks and receives from sponsors the appropriate assurance of device safety and effectiveness
![Page 18: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/18.jpg)
Achieving First Cycle Approvals and Clearances
• Meeting management performance goals with specific timeframes for determination and agreement meetings, informal pre-IDE meetings, pre-PMA meetings, pre-PMA filing meetings should be a critical feature of any future MDUFMA agreement
• Targeted strategies like special protocol assessments (SPA), and continuous marketing application (CMA) demonstrations should be considered
![Page 19: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/19.jpg)
COA and Postmarket Surveillance Studies
• Sponsor compliance with postmarket surveillance studies should be reported accurately. CDRH reporting and oversight should be improved
• FDA should issue guidance and outreach to IRBs to expedite approval and conduct of COA studies
![Page 20: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/20.jpg)
HDEs and Pediatric Devices • Reconsider restrictive HDE/HUD guidance
requiring sponsors to demonstrate that devices cannot be used for any other “medically plausible” subpopulations other than the population intended to be treated under a HDE designation
• Statutory and regulatory changes needed to raise the patient population cap and to remove the profit restriction on HDE/HUDs
• Reduce unnecessary burdens and clarify diversity of study designs permissible to establish safety and effectiveness, as well as the different forms that “valid scientific evidence” may take, for pediatric populations
![Page 21: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/21.jpg)
Critical Path Initiative
• As medical technology advances at an accelerating rate, the Critical Path Initiative is an important opportunity to advance the scientific basis for CDRH operations
• NVCA is committed to collaborating with FDA to identify new scientific and regulatory opportunities to get safe and effective medical devices and radiological products to market more quickly
![Page 22: MDUFMA Reauthorization: Key Issues For Venture Capital Jack Lasersohn](https://reader034.fdocuments.net/reader034/viewer/2022042822/5681305d550346895d962566/html5/thumbnails/22.jpg)
Thank You